AstraZeneca expands AI partnership with Immunai in deal worth up to $37.5 million
Biotech company’s immune-system modeling platform will continue supporting oncology drug development through 2027.
AstraZeneca is expanding its collaboration with Immunai, deepening a multi-year partnership centered on the use of artificial intelligence in oncology drug development. Under the expanded agreement, Immunai will be eligible to receive up to $37.5 million during 2026 and 2027.
The deal extends an existing collaboration between the two companies through 2027 and reflects the growing role of AI-driven platforms in pharmaceutical research, particularly in areas such as biomarker discovery, patient selection, and the analysis of treatment responses.
At the center of the collaboration is Immunai’s AMICA-OS platform, an AI operating system designed to model the human immune system using one of the industry’s largest clinical immunology datasets at single-cell resolution. The platform combines large-scale immune-system data with foundation AI models to generate insights intended to support oncology clinical development.
Under the agreement, AstraZeneca will continue using the platform across its oncology programs, including for biomarker discovery, patient stratification, dose optimization, and mechanism-of-action analysis.
The partnership builds on earlier agreements between the companies. In 2024, AstraZeneca began using Immunai’s platform across oncology clinical programs, and in 2025 the collaboration expanded into inflammatory bowel disease research.
“Across AstraZeneca, we are continuously investing in frontier AI models and solutions to inform clinical development decisions and derive novel mechanistically informed biomarkers,” said Jorge Reis-Filho, AstraZeneca’s Chief of AI for Science Innovation. “The expansion of this ongoing collaboration is a reflection of our conviction in the transformative potential of AI to improve patient outcomes.”
Immunai CEO Noam Solomon said the broader agreement signals confidence in the company’s technology platform.
“The fact that AstraZeneca continues to deepen this collaboration is a strong signal for us that the platform is delivering,” Solomon said. “We are focused on generating insights that are mechanistically grounded and clinically relevant.”
Founded to map and decode the human immune system using machine learning and single-cell genomics, Immunai has become part of a growing wave of AI-focused biotechnology companies seeking to position themselves as infrastructure providers for pharmaceutical research rather than traditional drug developers.
The company employs more than 170 people, is headquartered in New York City, and has raised nearly $270 million to date.
